The independent source for health policy research, polling, and news.
2,421 - 2,440 of 15,468 Results
The Supreme Court on April 21 ruled that the abortion pill mifepristone should remain widely available while the lower courts consider the issue, blocking earlier rulings that banned or restricted access to the drug. KFF Health News’ Julie Rovner joined NPR’s “Weekend All Things Considered” to discuss the complicated case.
A group of former professional athletes traveled to Jamaica to try psychedelics as a way to help cope with the aftereffects of concussions and a career of body-pounding injuries. Will this still largely untested treatment work?
The federal government’s ambitious plan to end the HIV epidemic, launched in 2019, has generated new ways to reach at-risk populations in targeted communities across the South. But health officials, advocates, and people living with HIV worry significant headwinds will keep the program from reaching its goals.
Two transgender lawmakers are trying to lay the groundwork for LGBTQ-friendly policies in a conservative state, but tensions are running high as the legislative session nears its end.
Billions of dollars are headed to state and local governments to address the opioid crisis. Policy experts and advocates expect the federal government to play a role in overseeing the use of the money. Failure to do so, they say, could lead to wasted opportunities. And, since Medicaid helps pay health care costs, the feds could have a claim to portions of states’ opioid settlements.
The Supreme Court is considering the future of the abortion pill mifepristone, after GenBioPro sued the FDA over limitations that effectively block generic production of the drug, a major part of the market. Congress is considering proposals that would impose Medicaid work requirements, crack down on pharmacy benefit managers, and more. And President Joe Biden moved to expand health coverage to young immigrants known as “Dreamers.” Rachel Cohrs of Stat, Sandhya Raman of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KFF Health News’ Mary Agnes Carey to discuss these issues and more.
Lisa French was told her surgery would cost $1,337. But the hospital sent her a bill for $229,000, then sued her. The case went all the way to the Colorado Supreme Court. The court’s ruling could have major implications for determining a “reasonable price” in health care.
The private equity-backed practice has been known to demand more than $100,000 in charges or penalties. One patient is fighting back.
Gov. Gavin Newsom’s ambitious experiment in health care is supposed to cut costs as it fills the needs of hard-to-reach people. The program’s start is chaotic and limited, but it shows promise.
Advocates for improving rural health pushed for the CDC to extend its rural health focus by creating an Office of Rural Health. They hope the agency will commit to rural health research and provide analyses that lead to good public health policies for rural communities.
Online platforms are overflowing with testimonials for GLP-1s. The drugs show promise for inducing weight loss, but many aren’t FDA-approved for that use.
Millions of Americans suffer from long covid, which can have debilitating physical effects, including fatigue and difficulty breathing. Yet many patients feel they’re on their own.
The median life expectancy for a U.S. baby born with Down syndrome jumped from about four years in 1950 to 58 years in the 2010s. That’s largely because they no longer can be denied lifesaving care, including surgeries for heart defects. But now, aging adults with Down syndrome face a health system unprepared to care for them.
KFF Health News and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
A growing number of states — including Maryland, Colorado, and Massachusetts — are using tax forms to point people toward lower-cost health coverage available through state insurance marketplaces.
The legality and availability of the abortion pill mifepristone is in question after a federal judge in Texas canceled the FDA’s approval of the first drug used in the two-drug medication abortion regimen. A 5th Circuit Court of Appeals panel overruled that decision in part, saying the pill should remain available, but only under the onerous restrictions in place before 2016. Meanwhile, another federal judge in Washington state issued a ruling in a separate case that conflicts with the Texas decision, ordering the FDA not to roll back any of its restrictions on the drug. Victoria Knight of Axios, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more.
Californians 85 and older are especially susceptible to malnutrition. They accounted for almost three in five malnutrition deaths in the state last year.
Horizon Therapeutics, which Amgen is acquiring for about $28 billion, grew large by snapping up cheap drugs from other companies, marketing them to perfection, and jacking up prices.
KFF Health News and CBS News recently reported that multiple lawsuits allege the device has led to grievous injuries to patients’ mouths, resulting in loss of teeth.
© 2026 KFF